NCT04556617

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Opna Bio LLC · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions

• Metastatic Castration-resistant Prostate Cancer

Interventions

Type	Name	Description
DRUG	PLX2853 20 mg	PLX2853 tablets
DRUG	Olaparib	Olaparib tablets
DRUG	Abiraterone acetate	Abiraterone acetate tablets
DRUG	Prednisone	Prednisone (or equivalent) tablets
DRUG	PLX2853 40 mg	PLX2853 tablets
DRUG	PLX2853 80 mg	PLX2853 tablets

Timeline

• Start date: 2020-09-21
• Primary completion: 2022-05-24
• Completion: 2022-05-24
• First posted: 2020-09-21
• Last updated: 2025-04-08
• Results posted: 2025-04-08

Locations

8 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study